


# Antiarrhythmic Drugs

**Dr. Ahmed Z. Alanazi**

**Assistant Professor**

**Department of Pharmacology & Toxicology, College of  
Pharmacy, King Saud University**




# Cardiovascular Pharmacology

- Antiarrhythmic drugs
- Drugs in heart failure
- Antihypertensive drugs
- Antianginal drugs
- Antihyperlipidemic drugs

# Learning objectives

*By the end of this lecture, students should be able to:*

- **Understand** definition of **arrhythmias** & their different types
- **Describe** different classes of **Antiarrhythmic drugs** & their mechanism of action
- **Understand** their pharmacological actions, clinical uses, adverse effects & their interactions with other drugs.







**Cardiac Conduction System**

# **CARDIAC CONDUCTION SYSTEM**

- S.A. node**
- Inter-nodal pathways**
- A.V. node**
- Bundle of His and branches**
- Purkinje fibers**


# Electrocardiogram (ECG)




**Electrical and Mechanical Events**

# CARDIAC ACTION POTENTIAL

Skeletal action potential:




Cardiac action potential:



# CARDIAC ACTION POTENTIAL


## Pacemaker (SA node)






# CARDIAC ACTION POTENTIAL


## Non-pacemaker (ventricular muscle)



# Fast-Response Action Potential (e.g., ventricular myocyte)



# Difference between pacemaker and non-pacemaker action potential




# WHAT IS ARRHYTHMIA?

An **abnormality** in the :

■ rate ..... high= tachycardia


low = bradycardia

## Normal Sinus Rhythm




Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
60-100 bpm	Regular	Before each QRS, identical	.12 to .20	<.12

# Sinus Tachycardia



Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
> 100 bpm	Regular	Before each QRS, identical	.12 to .20	<.12

# Sinus Bradycardia



Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
< 60 bpm	Regular	Before each QRS, identical	.12 to .20	<.12


# WHAT IS ARRHYTHMIA?

An **abnormality** in the :


- rate ..... high= tachycardia  
low = bradycardia
- regularity ..... Extrasystoles  
(PAC, PVC)



## Multifocal PVC's: more than one shape



# Atrial Fibrillation





Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
A: 350-650 bpm V: Slow to rapid	Irregular	Fibrillatory (fine to coarse)	N/A	<.12



## 2. Disorders of impulse conduction

May result in abnormality in rate:

- Bradycardia (if have AV block)
- Tachycardia (if reentrant circuit occurs)




# Disturbances in conduction

1st degree AV Block



2nd degree AV Block  
Wenkebach/Mobitz I



2nd degree AV Block  
Mobitz II



3rd degree AV Block



# Therapeutic use of antiarrhythmic drugs

**The ultimate goal of therapy**



**Restore normal rhythm & conduction**



**Maintenance of  
normal rhythm**



**Prevention of more  
serious arrhythmias**

# How antiarrhythmic drugs produce these effects?

- **Slow conduction velocity**
- **Altering the excitability of cardiac cells by prolonging the effective refractory period (ERP)**
- **Suppressing ectopic pacemaker activity by inhibiting phase 4 slow depolarization**

**CLASSIFICATION  
OF  
ANTIARRHYTHMIC DRUGS**



# Vaughn Williams classification

## CLASS I

Sodium channel blockers

## CLASS II:

$\beta$ - adrenoceptor blockers

## CLASS III:

Potassium channel blockers

## CLASS IV:

Calcium channel blockers.

# CLASS I



Drugs that block the influx of **Na ions** through **Na channels**



1- decrease the rate of rise of rapid depolarization (Phase 0)

2- decrease phase 4 slow depolarization (suppress pacemaker activity)

(membrane stabilizing effect)



# CLASS I


- **Sub classified according to their effect on action potential duration (APD) :**
  - **la** : prolong APD
  - **lb** : shorten APD
  - **lc** : Minimal effects on APD

# Type I - Na Channel Blockers

## Class I Antiarrhythmic Drug Effects

Increasing AP increases the QT interval

On the Ventricular Action Potential:



On the ECG:

↑QRS & ↑QT

↓QT

↑↑QRS

Blocks Na (I) and K (III) channels

Slow rate of rise

Increase ERP

Increase AP

Short Repolarization

Decrease in AP

Decrease ERP

Pure Na channel blockers

Depress rate of rise

Slows conduction velocity

No change in AP

# CLASS I a


**Ia : prolong action potential duration**

**e.g.**

**Quinidine**

**Procainamide**

Class IA drugs slow Phase 0 depolarization, prolong action potential, and slow conduction.



# CLASS I a QUINIDINE

## Other pharmacological actions :

1- Anticholinergic effect:



Increase conduction through the A.V. node

(risk of ventricular tachycardia)

2-  $\alpha$ -adrenergic blocking effect:



may cause vasodilatation & reflex sinus tachycardia

(seen more after I.V. dose)

3- ECG changes:

- P-R and Q-T prolongation
- widens QRS complex

**CLASS I a**

**QUINIDINE**

**Therapeutic uses:**


- **atrial flutter & fibrillation**
- **maintaining sinus rhythm after cardioversion**



# CLASS Ia QUINIDINE

## Adverse effects :

quinidine syncope: episodes of fainting due to **torsades de pointes** (twisting of the spikes) developing at therapeutic plasma levels




# Torsades de pointes

- may terminate spontaneously or lead to



**fatal ventricular fibrillation**

## Ventricular Fibrillation



Heart Rate	Rhythm	P Wave	PR interval (in seconds)	QRS (in seconds)
300-600	Extremely irregular	Absent	N/A	Fibrillatory baseline

**CLASS I a**  
**QUINIDINE**

**Adverse effects :**

❖ **Anticholinergic adverse effects:**

- **Dry mouth**
- **Blurred vision**
- **Urinary retention**
- **N/V/D**

❖ **Hypotension**

- **due to depressing contractility & vasodilatation**

**GIVEN ORALLY (Rarely given I.V.)**

## CLASS I a

### PROCAINAMIDE

**Similar to quinidine except :**

**1- less toxic on the heart...**

**can be given I.V.**

**2- more effective in ventricular than in**

**atrial arrhythmias**

**3 – Less anticholinergic or  $\alpha$ -blocking actions**

**CLASS I a**  
**PROCAINAMIDE**

**Adverse effects:**

- In *long term* therapy it causes reversible  
**lupus erythematosus-like syndrome**
- Hypotension
- Torsades de pointes (at toxic dose)
- Hallucination & psychosis

# CLASS I b


- **Shorten action potential duration**

**e.g.**

**Lidocaine**

**Mexiletine**

Class IB drugs shorten Phase 3 repolarization and decrease the duration of the action potential.



**CLASS Ib**  
**LIDOCAINE**

**Therapeutic uses :**

treatment of **emergency** ventricular arrhythmias

e.g. :

1 - during surgery

2 - following acute myocardial infarction

- **NOT** effective in atrial arrhythmias
- **NOT** effective orally (3% bioavailability)
- Only given I.V. bolus or slow infusion
- $t_{1/2} = 2$  hours



**CLASS Ib**  
**LIDOCAINE**

**Adverse effects:**

- ❑ hypotension
- ❑ similar to other local anesthetics,  
causes CNS adverse effects such as:
  - paresthesia
  - tremor
  - dysarthria (slurred speech)
  - tinnitus
  - confusion
  - **convulsions**

**CLASS Ib**  
**MEXILETINE**

**- EFFECTIVE ORALLY**

**Therapeutic uses :**

**1- ventricular arrhythmia**

**2- digitalis-induced arrhythmias**

**$t_{1/2} = 10$  hours**

**ADVERSE EFFECTS :**

**1- nausea, vomiting**

**2- tremor, drowsiness, diplopia**

**3- arrhythmias & hypotension**


# CLASS Ic

- have no effect on action potential duration

e.g.

**Flecainide**

Class IC drugs markedly slow Phase 0 depolarization.




**CLASS Ic**  
**FLECAINIDE**

**Therapeutic uses :**

- **supraventricular arrhythmias**
- **Wolff-Parkinson-White syndrome**
- **very effective in ventricular arrhythmias, but very high risk of **proarrhythmia****
- **should be reserved for resistant arrhythmias**

# Wolff-Parkinson-White syndrome

- Pre-excitation of the ventricles due to an accessory pathway known as the Bundle of Kent.



**CLASS Ic**  
**FLECAINIDE**

**Adverse effects:**

**1- proarrhythmia**

**2- CNS :**

**dizziness, tremor, blurred vision,  
abnormal taste sensations, paraesthesia**

**3- heart failure due to -ve inotropic effect.**

# CLASS II DRUGS

## $\beta$ - ADRENOCEPTOR BLOCKERS

pharmacological actions :

block  $\beta_1$ - receptors in the heart



reduce the sympathetic effect on the heart



1 - decrease automaticity of S.A. node &  
ectopic pacemakers

2 - prolong RP (slow conduction) of the A.V node



# CLASS II DRUGS

## $\beta$ - ADRENOCEPTOR BLOCKERS

### Therapeutic uses :

**1- atrial arrhythmias associated with emotion:**

- e.g. :**
- after exercise**
  - thyrotoxicosis**

**2- WPW**

**3- digitalis-induced arrhythmias.**

# CLASS II DRUGS

## $\beta$ - ADRENOCEPTOR BLOCKERS

### Therapeutic uses :

#### **Esmolol :**

- very short acting (half-life = 9 min.)
- given I.V. for rapid control of ventricular rate in patients with atrial flutter or fibrillation

#### **Propranolol, Atenolol, Metoprolol :**

- used in patients who had myocardial infarction to reduce incidence of sudden death due to ventricular arrhythmias.

# **CLASS III DRUGS**

- **Prolong the action potential duration & RP**
- **Prolong phase 3 repolarization**

Class III drugs prolong Phase 3 repolarization, without altering Phase 0.



# CLASS III DRUGS

## AMIODARONE

### pharmacological actions :

- prolongs action potential duration & therefore prolongs RP (**Main effect**)
- additional class Ia, II & IV effects
- vasodilating effects  
(due to its  $\alpha$ - &  $\beta$ -adrenoceptor blocking effects & its calcium channel blocking effects)

# CLASS III DRUGS

## AMIODARONE

### Therapeutic uses :

- 1- main use : serious resistant ventricular arrhythmias
- 2- maintenance of sinus rhythm after cardioversion
- 3- resistant supraventricular arrhythmias (e.g. WPW)

# CLASS III DRUGS

## AMIODARONE

### Adverse effects:

- exacerbation of ventricular arrhythmias (**high dose**)
- bradycardia & heart failure
- pulmonary fibrosis
- hyper- or hypothyroidism
- photodermatitis & skin deposits (**avoid exposure to the sun**).

## CLASS III DRUGS

### AMIODARONE

#### Adverse effects:

- **Neurological:**

  - e.g. tremors & peripheral neuropathy

- **nausea, vomiting & constipation**

- **corneal micro deposits**

- **hepatocellular necrosis**



# CLASS III DRUGS

## AMIODARONE

### Pharmacokinetics:

- extremely long  $t_{1/2} = 13 - 103$  DAYS
- metabolized by CYP3A4 and CYP2C8 to its major active metabolite: **N-desethylamiodarone**
- eliminated primarily by hepatic metabolism
- cross placenta & appear in breast milk.

# CLASS III DRUGS

## AMIODARONE

### Drug Interactions:

1 - Co-administration of amiodarone with drugs that prolong the QT interval increases the risk of Torsades de Pointes

e.g. :

macrolide antibiotics (Clarithromycin, Erythromycin)

azole antifungals (Ketoconazole)

# CLASS III DRUGS

## AMIODARONE

### Drug Interactions:

2- Drugs (or substances) that **inhibit** CYP3A4 & CYP2C8 enzymes cause increase in serum concentration of amiodarone

**e.g. : Loratadine, Ritonavir, Trazodone  
Cimetidine, Grapefruit juice**

3- Drugs that **induce** these enzymes

Cause decrease in serum concentration of amiodarone

**e.g. : Rifampin**

# **PURE CLASS III**

## **Ibutilide**

- **Given by rapid I.V. infusion**
- **Used for the acute conversion of atrial flutter or fibrillation to normal sinus rhythm**
- **Causes QT interval prolongation**  
**(may cause torsades de pointes).**

# **Class 1V**

## **Calcium channel blockers**

### **Verapamil, Diltiazem**

- **main site of action is A.V.N & S.A.N**  
**cause:**
  - **slowing of conduction**
  - **prolongation of ERP**

# Class 1V

## Calcium channel blockers

### Therapeutic uses :

- 1- atrial arrhythmias
- 2- re-entry supraventricular arrhythmias  
e.g. WPW
- 3- NOT effective in ventricular arrhythmias.

# ADENOSINE

## Mechanism of action :

- inhibits c.AMP by binding to adenosine **A1** receptors causing the following actions:

1 - opening of potassium channels


(hyperpolarization)

2 - decreasing conduction velocity mainly at AV node

(negative dromotropic effect)

3- inhibiting phase 4 pacemaker action potential at SA node

(negative chronotropic effect)





# ADENOSINE

## Therapeutic uses :

- drug of choice for acute management of paroxysmal supraventricular tachycardia
  - preferred over verapamil  
(safer & does not depress contractility)
- half-life = less than 10 sec**

# ADENOSINE

## Adverse effects:

- flushing in about 20% of patients
- shortness of breath & chest burning in 10% of patients (due to bronchospasm)
- brief AV block (contraindicated in heart block)

# **New Antiarrhythmic Drugs**

## **Dronedarone**

- **a noniodinated congener of amiodarone**
- **has antiarrhythmic properties belonging to all four classes**
- **Used for maintenance of sinus rhythm following cardioversion in patients with atrial flutter or fibrillation.**

# New Antiarrhythmic Drugs

## Dronedarone

### WARNINGS

- should **not** be used in patients with severe (class IV) heart failure. Risk of death may be increased in these patients
- should **not** be used in patients with permanent atrial fibrillation. Risk of death & stroke, may be increased in these patients.

# BRADYARRHYTHMIAS


## ATROPINE

- used in sinus bradycardia after myocardial infarction & in heart block
- in emergency heart block **isoprenaline** may be combined with atropine **(caution)**

# NONPHARMACOLOGIC THERAPY OF ARRHYTHMIAS

## Implantable Cardiac Defibrillator (ICD)

- can automatically detect & treat fatal arrhythmias such as ventricular fibrillation



Thank you

